Global Cause
In this issue
-
The business case for women’s health equity
Women continue to be left behind in healthcare access and innovation worldwide. Addressing this is critical for health equity. But it also presents a significant business opportunity. Women’s healthcare gaps Across low- and middle-income countries (LMICs), women face major barriers to accessing healthcare. Around 1.8 billion women in these countries are affected by at least...
-
s Sponsored
AMR and sepsis: The hidden crisis for cancer care
Modern cancer treatment is more targeted and effective than ever. But for patients whose immune systems have been weakened by chemotherapy, surgery or transplant, a resistant infection can rapidly turn progress into crisis. For some cancer patients, the immediate threat to survival isn’t the malignancy, but infection. Threat of infections and sepsis If an infection...
-
s Sponsored
How drug-resistant infections can delay vital cancer treatments
A cancer survivor recalls how she had to stop treatment to manage a resistant infection — and why the experience has prompted her to call for mandatory resistance testing. When she was 43, Ana Mazanishvili was diagnosed with breast cancer. She elected to have a double mastectomy, but as if that wasn’t traumatic enough, she...
-
s Sponsored
What is the single most important message for policymakers?
Addressing AMR-restrained patients’ access and market failure requires a fundamental shift away from volume-based toward value-contribution valuation healthcare policies. Why is antimicrobial resistance (AMR) becoming one of the greatest threats to patients’ lives and to our modern medicine? Worldwide, there are 4.95 million AMR-associated deaths annually. They’re projected to exceed 10 million deaths yearly by...
-
s Sponsored
How One Health helps build global resilience
One Health offers a practical blueprint for integrating health approaches and interventions to build resilience, translating complexity into coordinated, effective action. In Africa, one in five bacterial infections1 is already showing signs of Antimicrobial Resistance (AMR). One Health approaches systematically tackle this, guided by the AMR National Action Plans (NAPs). Turning integration into impact Yet,...
-
s Sponsored
A faster path to infectious disease breakthroughs
The COVID-19 pandemic exposed how vulnerable the world remains to infectious diseases. Faster, more efficient clinical development pathways accelerate access to vaccines and therapeutics. Infectious diseases continue to disproportionately affect low- and middle-income countries, where healthcare, diagnostics and treatment access are often limited, and healthcare systems are more vulnerable to disruption. Product development challenges Despite...
-
What it will take to end malaria — and why Britain’s leadership still matters
Malaria still kills over 600,000 people every year,1 even though it’s preventable and treatable. Children under five in Africa carry the heaviest burden — school lessons missed, futures cut short. In too many communities, health systems are stretched beyond their limits, trying to protect mothers and babies from a disease we can consign to history. Pivotal moment for malaria efforts After two decades of hard-won...
-
Beyond trials: Implementation research that strengthens health systems
Developing a safe and effective vaccine is only part of the challenge. Ensuring it reaches the right people, at the right time and that its performance in real settings is rigorously documented, is equally critical. This is the work of implementation research, which bridges clinical evidence and public health impact, and one that European Vaccine...
-
Rethinking diagnostics in the fight against AMR — from analytical accuracy to real-world clinical utility
In microbiological diagnostics, speed, accuracy and access determine survival. Yet the pathway from discovery to bedside to policy remains fragmented, with weak linkages between analytical validation and real-world performance. Limited contextualisation of diagnostics across diverse clinical settings, alongside persistent affordability barriers, continues to constrain translation of innovation into measurable impact on antimicrobial resistance (AMR). Multi-dimensional...